1. Home
  2. ENTX vs SCWO Comparison

ENTX vs SCWO Comparison

Compare ENTX & SCWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • SCWO
  • Stock Information
  • Founded
  • ENTX 2010
  • SCWO 2021
  • Country
  • ENTX Israel
  • SCWO United States
  • Employees
  • ENTX N/A
  • SCWO N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • SCWO Environmental Services
  • Sector
  • ENTX Health Care
  • SCWO Utilities
  • Exchange
  • ENTX Nasdaq
  • SCWO Nasdaq
  • Market Cap
  • ENTX 90.2M
  • SCWO 64.3M
  • IPO Year
  • ENTX 2018
  • SCWO N/A
  • Fundamental
  • Price
  • ENTX $2.55
  • SCWO $0.41
  • Analyst Decision
  • ENTX Strong Buy
  • SCWO
  • Analyst Count
  • ENTX 1
  • SCWO 0
  • Target Price
  • ENTX $10.00
  • SCWO N/A
  • AVG Volume (30 Days)
  • ENTX 86.5K
  • SCWO 401.3K
  • Earning Date
  • ENTX 03-07-2025
  • SCWO 03-28-2025
  • Dividend Yield
  • ENTX N/A
  • SCWO N/A
  • EPS Growth
  • ENTX N/A
  • SCWO N/A
  • EPS
  • ENTX N/A
  • SCWO N/A
  • Revenue
  • ENTX $99,000.00
  • SCWO $313,930.00
  • Revenue This Year
  • ENTX N/A
  • SCWO N/A
  • Revenue Next Year
  • ENTX N/A
  • SCWO $5,180.00
  • P/E Ratio
  • ENTX N/A
  • SCWO N/A
  • Revenue Growth
  • ENTX 607.14
  • SCWO N/A
  • 52 Week Low
  • ENTX $0.71
  • SCWO $0.36
  • 52 Week High
  • ENTX $3.35
  • SCWO $1.99
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 61.93
  • SCWO 23.40
  • Support Level
  • ENTX $2.00
  • SCWO $0.54
  • Resistance Level
  • ENTX $2.62
  • SCWO $0.58
  • Average True Range (ATR)
  • ENTX 0.18
  • SCWO 0.06
  • MACD
  • ENTX 0.01
  • SCWO -0.00
  • Stochastic Oscillator
  • ENTX 96.77
  • SCWO 17.29

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About SCWO 374Water Inc.

374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The business activities of the company include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.

Share on Social Networks: